Liver Transplantation is a Preferable Alternative to Palliative Therapy for Selected Patients with Advanced Hepatocellular Carcinoma

scientific article

Liver Transplantation is a Preferable Alternative to Palliative Therapy for Selected Patients with Advanced Hepatocellular Carcinoma is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1083535021
P356DOI10.1245/S10434-017-5789-3
P698PubMed publication ID28160137

P50authorIan D McGilvrayQ50073694
Aloysious AravinthanQ53134884
Hla-Hla TheinQ56997867
Markus SelznerQ87749637
P2093author name stringEberhard L Renner
Mamatha Bhat
Anand Ghanekar
David R Grant
Mark S Cattral
Paul D Greig
Gonzalo Sapisochin
Nazia Selzner
Nicolas Goldaracena
Leslie B Lilly
Assaf Issachar
Silvio G Bruni
Adam C Doyle
Boraiah Sreeharsha
P2860cites workLiver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survivalQ46743120
Benefit of Treating Hepatocellular Carcinoma Recurrence after Liver Transplantation and Analysis of Prognostic Factors for Survival in a Large Euro-American Series.Q47700671
Response to therapy as a criterion for awarding priority to patients with hepatocellular carcinoma awaiting liver transplantation.Q51715162
Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantationQ26772329
Management of hepatocellular carcinoma: An updateQ27860530
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinomaQ27860783
Liver transplantation for advanced hepatocellular carcinomaQ28074653
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialQ29617955
Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinomaQ29617957
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosisQ29619508
Defining long-term outcomes with living donor liver transplantation in North AmericaQ30356729
Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experienceQ34630506
Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma.Q36673829
Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listingQ36716640
The Degree of Lipiodol Accumulation Can Be an Indicator of Successful Treatment for Unresectable Hepatocellular Carcinoma (HCC) Patients - in the Case of Transcatheter Arterial Chemoembolization (TACE) and External Beam Radiotherapy (EBRT).Q37133637
Liver transplantation for hepatocellular carcinoma: beyond the Milan criteriaQ37252475
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysisQ37341959
Squaring the circle of selection and allocation in liver transplantation for HCC: An adaptive approach.Q37348887
Modified RECIST (mRECIST) assessment for hepatocellular carcinomaQ37696396
The place of downstaging for hepatocellular carcinomaQ37729494
Waitlist priority for hepatocellular carcinoma beyond milan criteria: a potentially appropriate decision without a structured approachQ38168622
Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma.Q38706131
Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.Q38711169
Early sorafenib-related adverse events predict therapy response of TACE plus sorafenib: A multicenter clinical study of 606 HCC patientsQ38886929
In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?Q38984450
Health care costs associated with hepatocellular carcinoma: a population-based studyQ39489363
Predicting Mortality in Patients Developing Recurrent Hepatocellular Carcinoma After Liver Transplantation: Impact of Treatment Modality and Recurrence CharacteristicsQ39585608
Defining Benchmarks for Major Liver Surgery: A multicenter Analysis of 5202 Living Liver DonorsQ39585622
The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation studyQ39766876
Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European studyQ40741790
Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validationQ41208111
Role of liver transplantation in cancer therapyQ41374922
Live donor liver transplantation in high MELD score recipients.Q43254448
Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imagingQ43883499
The global NAFLD epidemicQ44238213
Hepatocellular carcinoma: Ablate and wait versus rapid transplantationQ45146349
The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma.Q46682103
P433issue7
P304page(s)1843-1851
P577publication date2017-02-03
P1433published inAnnals of Surgical OncologyQ2853069
P1476titleLiver Transplantation is a Preferable Alternative to Palliative Therapy for Selected Patients with Advanced Hepatocellular Carcinoma
P478volume24

Reverse relations

cites work (P2860)
Q92519577Extremes of Liver Transplantation for Hepatocellular Carcinoma
Q88791892Hepatocellular carcinoma: when is liver transplantation oncologically futile?
Q55275430Ischemia-reperfusion injury and the risk of hepatocellular carcinoma recurrence after deceased donor liver transplantation.
Q92796957Recurrence of Hepatocellular Carcinoma After Liver Transplantation: A Single-Center Experience

Search more.